**ZINNAT**

Cefuroxime axetil

**Qualitative and Quantitative Composition**

ZINNAT Suspension contains granules of cefuroxime axetil for oral suspension. Reconstitution of multidose bottles as directed yields a suspension containing 125 mg or 250 mg of cefuroxime (as cefuroxime axetil) in each 5 ml. ZINNAT Sachets contain 125 mg or 250 mg granules of cefuroxime (as cefuroxime axetil) for single dose administration when reconstituted.

**Pharmaceutical Form**

Dry, white to off-white, tutti-frutti flavored granules for oral suspension.

**Clinical Particulars**

**Indications**

ZINNAT is an oral prodrug of the bacterioidal cephalosporin antibiotic cefuroxime, which is resistant to most (β/β')-lactamases and is active against a wide range of Gram-positive and Gram-negative organisms. It is indicated for the treatment of infections caused by susceptible bacteria. Susceptibility to ZINNAT will vary with geography and time and local susceptibility data should be consulted where available (see Pharmacological properties, Pharmacodynamics).

**Indications include**

- upper respiratory tract infections for example, ear, nose and throat infections, such as otitis media, sinusitis, tonsillitis and pharyngitis
- lower respiratory tract infections for example, pneumonia, acute bronchitis, and acute exacerbations of chronic bronchitis
- genito-urinary tract infections for example, pyelonephritis, cystitis and urethritis
- skin and soft tissue infections for example, furunculosis, pyoderma and impetigo
- gonorrhea, acute uncomplicated gonococcal urethritis, and cervicitis
- treatment of early Lyme disease and subsequent prevention of late Lyme disease in adults and children over 12 years old.

**Dosage and Administration**

The usual course of therapy is seven days (range 5 to 10 days). For optimal absorption, ZINNAT should be taken with food.

**Adults**

Most infections 250 mg twice daily
Urinary tract infections 125 mg twice daily
Mild to moderate lower respiratory tract infections e.g. bronchitis 250 mg twice daily
More severe lower respiratory tract infections, or if pneumonia is suspected 500 mg twice daily
Pyelonephritis 250 mg twice daily
Uncomplicated gonorrhea single dose of 3 g
Lyme disease in adults and children over the age of 12 years 500 mg twice daily for 20 days

**Children**

When prescription of a fixed dose is preferred, the recommended dose for most infections is 125 mg twice daily. In children aged two years or older with otitis media or where appropriate, with more severe infections, the dose is 250 mg twice daily, to a maximum of 500 mg daily. There are no clinical trial data available on the use of ZINNAT in children under the age of 3 months. In infants and children 3 to 12 years of age the 10 mg/kg twice daily for most infections, to a maximum of 250 mg daily. In otitis media or more severe infections the recommended dose is 15 mg/kg twice daily to a maximum of 500 mg daily.

The following two tables, divided by age group and weight, serve as a guideline for simplified administration from measuring spoons (5 ml) for the 125 mg/5 ml or the 250 mg/5 ml multi-dose suspension, and 125 mg or 250 mg single dose sachets.

### 10 mg/kg dosage for most infections

<table>
<thead>
<tr>
<th>Age</th>
<th>Approximate weight range (kg)</th>
<th>Dose (mg) twice daily</th>
<th>No. of measuring spoons (5 ml) or sachets per dose</th>
<th>125 mg</th>
<th>250 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 - 6 months</td>
<td>4 - 6</td>
<td>40 - 60</td>
<td>½</td>
<td>½</td>
<td>½</td>
</tr>
<tr>
<td>6 months - 2 years</td>
<td>6 - 12</td>
<td>60 - 120</td>
<td>½ - 1</td>
<td>½</td>
<td>½ - 1</td>
</tr>
<tr>
<td>2 - 12 years</td>
<td>12 - more than 20</td>
<td>125</td>
<td>1</td>
<td></td>
<td>½</td>
</tr>
</tbody>
</table>

**Contraindications**

Patients with known hypersensitivity to cephalosporin antibiotics.

**Warnings and Precautions**

Special care is indicated in patients who have experienced an allergic reaction to penicillins or other β-lactamases.

As with other antibiotics, use of ZINNAT may result in overgrowth of other non-susceptible organisms (e.g. enterococci and Clostridium difficile), which may require interruption of treatment. Pseudomembranous colitis has been reported with the use of antibiotics and may range in severity from mild to life-threatening. Therefore, it is important to consider its diagnosis in patients who develop diarrhoea during or after antibiotic use. If prolonged or significant diarrhoea occurs or the patient experiences abdominal cramps, treatment should be discontinued immediately and the patient investigated further. The sucrose content of ZINNAT suspension and granules (see List of Excipients) should be considered when treating diabetic patients, and appropriate advice provided.

The Jarisch-Herxheimer reaction has been seen following ZINNAT treatment of Lyme disease. It results directly from the bactericidal activity of ZINNAT on the causative organism of Lyme disease, the spirochaete Borrelia burgdorferi. Patients should be reassured that this is a common and usually self-limiting consequence of antibiotic treatment of Lyme disease.

ZINNAT suspension contains aspartame, which is a source of phenylalanine and so should be used with caution in patients with phenylketonuria.

**Interactions**

Drugs which reduce gastric acidity may result in a lower bioavailability of cefuroxime compared with that of the fasting state and tend to cancel the effect of enhanced absorption after food. In common with other antibiotics, ZINNAT may affect the gut flora, leading to lower oestroegen reabsorption and reduced efficacy of combined oral contraceptives.

**Pregnancy and Lactation**

There is no experimental evidence of embryopathic or teratogenic effects attributable to ZINNAT but, as with all drugs, it should be administered with caution during the early months of pregnancy.
**Pharmacodynamics**

The prevalence of acquired resistance is geographically and time dependent and for select species may be very high. Local information on resistance is desirable, particularly when treating severe infections. In vitro susceptibility of microorganisms to Cefuroxime

Where clinical efficacy of cefuroxime axetil has been demonstrated in clinical trials this is indicated with an asterisk (*).

<table>
<thead>
<tr>
<th>Organisms for which acquired resistance may be a problem</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gram-Positive Aerobes:</td>
</tr>
<tr>
<td>Streptococcus pneumoniae*</td>
</tr>
<tr>
<td>Haemophilus influenzae* including ampicillin resistant strains</td>
</tr>
<tr>
<td>Haemophilus parainfluenzae*</td>
</tr>
<tr>
<td>Moraxella catarrhalis*</td>
</tr>
<tr>
<td>Neisseria gonorrhoeae* including penicillinase and non-penicillinase producing strains</td>
</tr>
</tbody>
</table>

| Gram-Negative Aerobes:                                  |
| Peptostreptococcus spp.                                 |
| Propionibacterium spp.                                 |

| Spirochetes:                                           |
| Borrelia burgdorferi*                                  |

**Adverse Reactions**

Adverse drug reactions to ZINNAT are generally mild and transient in nature. The frequency categories assigned to the adverse reactions below are estimates, as for most reactions suitable data (for example from placebo-controlled studies) for calculating incidence were not available. In addition, the incidence of adverse reactions associated with ZINNAT may vary according to the indication.

Data from large clinical studies were used to determine the frequency of very common to rare undesirable effects. The frequencies assigned to all other undesirable effects (i.e. those occurring at <1/10000) were mainly determined using post-marketing data and refer to a reporting rate rather than true frequency. Placebo-controlled trial data were not available. Where incidences have been calculated from clinical trial data, these were based on drug-related (investigator assessed) data.

The following convention has been used for the classification of frequency:

- Very common: ≥1/10
- Common: ≥1/100 to <1/10
- Uncommon: ≥1/1000 to <1/100
- Rare: ≥1/10000 to <1/1000
- Very rare: <1/10000

**Infections and infestations**

**Common:**

- Overgrowth of Candida

**Uncommon:**

- Eosinophilia

**Rare:**

- Haemolytic anaemia

Cephalosporins as a class tend to be absorbed onto the surface of red cells membranes and react with antibodies directed against the drug to produce a positive Coombs’ test (which can interfere with cross-matching of blood) and very rarely haemolytic anaemia.

**Immune system disorders**

**Hypersensitivity reactions including:**

- Skin rash
- Urticaria, pruritus
- Drug fever, serum sickness, anaphylaxis

**Nervous system disorders**

- Headache, dizziness

**Gastrointestinal disorders**

- Gastrointestinal disturbances including diarrhoea, nausea, abdominal pain

**Hepatobiliary disorders**

- Transient increases of hepatic enzyme levels, [ALT [SGPT], AST [SGOT], LDH]

**Skin and subcutaneous tissue disorders**

- Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (exanthematic necrolysis). See also Immune system disorders.

**Overdose**

**Signs and symptoms**

- Overdosage of cefuroxime can cause cerebral irritation leading to convulsions.

**Treatment**

- Serum levels of cefuroxime can be reduced by haemodialysis and peritoneal dialysis.

**Pharmacological Properties**

**Pharmacokinetics**

After oral administration, ZINNAT is absorbed from the gastrointestinal tract and rapidly hydrolysed in the intestinal mucosa and blood to release cefuroxime into the circulation. Absorption of cefuroxime is enhanced in the presence of food. Following administration of ZINNAT tablets peak serum levels (2.1 mg/l for a 125 mg dose, 4.1 mg/l for a 250 mg dose, 7.0 mg/l for a 500 mg dose and 13.6 mg/l for a 1 g dose) occur approximately 2 to 3 hours after dosing when taken with food.

The rate of absorption of cefuroxime from the suspension compared with the tablets is reduced, leading to lower peak serum levels and reduced systemic bioavailability (4-17% less).

**Distribution**

Protein binding has been variously stated as 33-50% depending on the methodology used.

**Metabolism**

Cefuroxime is not metabolised.

**Elimination**

The serum half-life is between 1 and 1.5 hours.

Cefuroxime is excreted by glomerular filtration and tubular secretion. Concurrent administration of probenecid increases the area under the mean serum concentrations time curve by 50%.

**Renal impairment**

Cefuroxime pharmacokinetics have been investigated in patients with various degrees of renal impairment. Cefuroxime elimination half-life increases with decrease in renal function which serves as the basis for dosage adjustment recommendations in this group of patients (See Dosage and Administration). In patients undergoing haemodialysis, at least 60% of the total amount of cefuroxime present in the body at the start of dialysis will be removed during a 4-hour dialysis period. Therefore, an additional single dose of cefuroxime should be administered following the completion of haemodialysis.

**Pre-clinical Safety Data**

Animal toxicity studies indicated that cefuroxime is of low toxicity with no significant findings.

**Pharmaceutical Particulars**

**List of Excipients**

- Aspartame
- Xanthan gum
- Acetasmurfate potassium
- Povidone K30
- Stearic acid
- Sucrose
- Tutti-frutti flavour
Sucrose Quantities

<table>
<thead>
<tr>
<th>Sucrose quantity (g per dose)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>125 mg/5 ml Suspension</td>
<td>3.062 g</td>
</tr>
<tr>
<td>250 mg/5 ml Suspension</td>
<td>2.289 g</td>
</tr>
<tr>
<td>125 mg Sachet</td>
<td>3.062 g</td>
</tr>
<tr>
<td>250 mg Sachet</td>
<td>6.123 g</td>
</tr>
</tbody>
</table>

Incompatibilities

None.

Shelf-Life

The expiry date of the granules is indicated on the packaging.

The reconstituted suspension when refrigerated between 2 and 8°C can be kept for up to 10 days.

Special Precautions for Storage

The reconstituted suspension must be refrigerated immediately at between 2 and 8°C.

Nature and Contents of Container

Multidose bottles

ZINNAT Suspension is supplied in Ph.Eur Type III amber glass bottles with an induction heat seal membrane containing either 125 mg/5 ml or 250 mg/5 ml product. Dosing syringes are available with multidose bottles of both strengths.

Sachets:

ZINNAT Suspension in sachets for oral use is supplied in paper/polyethylene/foil/ ethylenemethacrylic acid ionomer laminated sachet. When reconstituted as directed, it provides the equivalent of 125 mg or 250 mg of ZINNAT (as cefuroxime axetil) per sachet.

Instructions for Use/Handling

Constitution/Administration Instructions

Always shake the bottle vigorously before taking the medication.

The reconstituted suspension when refrigerated between 2 and 8°C can be kept for up to 10 days.

If desired ZINNAT suspension can be further diluted from multidose bottles in cold fruit juices, or milk drinks and should be taken immediately.

The reconstituted suspension or granules should not be mixed with hot liquids.

Directions for reconstituting suspension in multidose bottles

1. Shake the bottle to loosen the granules. Remove the cap and the heat-seal membrane. If the latter is damaged or not present, the product should be returned to the pharmacist.
2. Add the total amount of water to the bottle as stated on its label. Replace the cap.
3. Invert the bottle and rock vigorously (for at least 15 seconds) as shown below.
4. Turn the bottle into an upright position and shake vigorously.
5. Refrigerate immediately at between 2 and 8°C.
6. If using a dosing syringe, allow the reconstituted suspension to stand for at least one hour before taking the first dose.

Directions for using the dosing syringe

1. Remove the bottle cap and insert the syringe-collar assembly into the neck of the bottle. Press it down completely until the collar fits in the neck firmly. Invert the bottle and syringe.
2. Pull the plunger up the barrel until the barrels rim is aligned with the mark on the plunger corresponding to the required dose.
3. Turn the bottle and syringe into an upright position. While holding onto the syringe and the plunger to ensure that the plunger does not move, remove the syringe from the bottle, leaving the plastic collar in the bottle neck.
4. With the patient seated in an upright position, place the tip of the syringe just inside the patient’s mouth, pointing towards the inside of the cheek.
5. Press the plunger of the syringe in slowly to expel the medicine without causing choking. Do NOT squirt the medicine out in a jet.
6. After giving the dose, replace the bottle cap without removing the plastic collar. Dismantle the syringe and wash it thoroughly in fresh drinking water. Allow the plunger and the barrel to dry naturally.

Directions for reconstituting suspension from sachets

1. Empty granules from sachet into a glass.
2. Add a small volume of water.